Add time:07/13/2019         Source:sciencedirect.com

Involved in the tyrosine degradation pathway, 4-hydroxyphenylpyruvate dioxygenase (HPPD) is an important target for treating type I tyrosinemia. To discover novel HPPD inhibitors, we proposed a hydrophobicity-oriented drug design (HODD) strategy based on the interactions between HPPD and the commercial drug NTBC. Most of the new compounds showed improved activity, compound d23 being the most active candidate (IC50 = 0.047 μM) with about 2-fold more potent than NTBC (IC50 = 0.085 μM). Therefore, compound d23 is a potential drug candidate to treat type I tyrosinemia.

We also recommend Trading Suppliers and Manufacturers of 4-[(4-fluorobenzyl)oxy]benzoyl chloride (cas 1160249-58-0). Pls Click Website Link as below: cas 1160249-58-0 suppliers